308 related articles for article (PubMed ID: 1806441)
21. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
22. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
23. Ultrastructural, immunologic and clinical follow-up of five patients with HCL treated with interferon (IFN) for more than three years.
Mantovani G; Astara G; Curreli L; Lai P; Turnu E; Locci F; Lantini MS; Cossu M; Riva A; Del Giacco GS
Haematologica; 1992; 77(4):326-35. PubMed ID: 1427443
[TBL] [Abstract][Full Text] [Related]
24. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
25. [Rapid disappearance of M-protein in multiple myeloma complicated by pneumonia during treatment with HLBI].
Ashihara E; Oku N; Nishio A; Tuji K; Nakamura M
Rinsho Ketsueki; 1992 Dec; 33(12):1818-23. PubMed ID: 1479692
[TBL] [Abstract][Full Text] [Related]
26. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
Bell JB; Barfoot R; Iveson T; Powles RL; Millar BC
Br J Cancer; 1994 Oct; 70(4):646-51. PubMed ID: 7917911
[TBL] [Abstract][Full Text] [Related]
27. Characterization of cord blood lymphocyte subpopulations.
Keever CA
J Hematother; 1993; 2(2):203-6. PubMed ID: 7921975
[TBL] [Abstract][Full Text] [Related]
28. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
29. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
30. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
31. Effect of recombinant alpha-interferon administration on peripheral blood lymphocyte subpopulations and natural killer cell activity in patients with refractory anemia with excess of blasts.
Eliopoulos G; Coulocheri S; Vaiopoulos G; Alexandrakis M; Ganotakis E; Eliopoulos A; Yataganas X
Nouv Rev Fr Hematol (1978); 1991; 33(1):21-4. PubMed ID: 1945821
[TBL] [Abstract][Full Text] [Related]
32. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.
Takahashi T; Makiguchi Y; Hinoda Y; Kakiuchi H; Nakagawa N; Imai K; Yachi A
J Immunol; 1994 Sep; 153(5):2102-9. PubMed ID: 8051415
[TBL] [Abstract][Full Text] [Related]
33. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
35. The increase of CD5LOW+NK cells in patients with multiple myeloma and plasmacytoma.
Ishiyama T; Watanabe K; Fukuchi K; Yajima K; Koike M; Tomoyasu S; Tsuruoka N
Anticancer Res; 1994; 14(2B):725-30. PubMed ID: 7516640
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
37. Alpha interferon as first line therapy for angioimmunoblastic lymphoadenopathy. Possible value of DR+ cells in monitoring therapeutical response.
Milone G; Guglielmo P; Cacciola E; Calogero D; Giustolisi R
Haematologica; 1992; 77(6):524-5. PubMed ID: 1289192
[No Abstract] [Full Text] [Related]
38. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome.
Cetiner S; Demirhan O; Inal TC; Tastemir D; Sertdemir Y
Int J Immunogenet; 2010 Aug; 37(4):233-7. PubMed ID: 20477881
[TBL] [Abstract][Full Text] [Related]
39. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
[TBL] [Abstract][Full Text] [Related]
40. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
